Clinical study for the treatment of chronic active Epstein-Barr virus infection (CAEBV) in children by L-DEP regimen

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900020574

Enrollment

Unknown

Registered

2019-01-09

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic active Epstein-Barr virus infection (CAEBV)

Interventions

Case series:L-DEP regimen

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged younger than 18 years; 2. Newly diagnosed as CAEBV; 3. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Heart function above grade II (NYHA); 2. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2; 3. Allergic to Pegaspargase, doxorubicin or etopside; 4. Active bleeding of the internal organs; 5. uncontrollable infection; 6. history of acute and chronic pancreatitis; 7. Participate in other clinical research at the same time.

Design outcomes

Primary

Measure	Time frame
blood routine examination;glutamic-pyruvic transaminase;glutamic oxalacetic transaminase;fibrinogen;Plasma EBV-DNA;Whole blood EBV-DNA;Liver, spleen and lymph node size;Cerebrospinal fluid;Abdominal ultrasound;Vascular ultrasound;Head MRI;cardiac and the coronary arteries color ultrasound;	—

Secondary

Measure	Time frame
ferritin;triglyceride;hemophagocytosis;NK activity;sCD25;	—

Countries

China

Contacts

Public ContactZhang Rui

Beijing Children's Hospital, Capital Medical University

ruizh1973@126.com+86 18611106187

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026